Cav 3.2 inhibitor 1 是一种 T 型钙离子通道 (Calcium Channel) 抑制剂，与多巴胺受体 (D2 receptor) 结合亲和力较低。Cav 3.2 inhibitor 1 可用于身体和内脏疼痛的研究。

Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain [1].

Cav 3.2 inhibitor 1 (compound 3a, 0.3 μM) inhibits Cav3.2 activities by about 50% in Cav3.2-transfected HEK293 cells [1]. Cav 3.2 inhibitor 1 (1 and 10 μM) displays little binding affinity to D2 receptors [1]. Cav 3.2 inhibitor 1 (0.01-1 μM) inhibits T-currents in Cav3.1-expressing HEK293 cells [1].

Cav 3.2 inhibitor 1 (compound 3a, 10 mg/kg, i.p.) suppresses Cav3.2-dependent somatic and visceral pain in mice [1]. Cav 3.2 inhibitor 1 (8 nmol/mouse, i.c.v.) has no effect on long-lasting catalepsy in mice [1]. Animal Model: Colonic pain and referred hyperalgesia mice induced by intracolonic (i.col.) administration of Na 2 S at 5 nmol/mouse [1]. Dosage: 1-10 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Completely blocked the Na 2 S-induced colonic pain and referred hyperalgesia.

C32H39N3O

481.67

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years